Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

184
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
184
Pneumonia IV: Management01:28

Pneumonia IV: Management

304
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
304
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

224
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
224
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

239
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
239

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Radiological factors associated with the recurrence of <i>Mycobacterium avium complex</i> pulmonary disease: a multicentre retrospective cohort study.

Thorax·2026
Same author

Inhibition of SRC prevents bone metastasis of breast cancer by blocking metastatic cell motility and bone directionality.

Theranostics·2026
Same author

Prognostic Value of the Eosinophil-to-Neutrophil Ratio for In-Hospital Mortality in Patients Hospitalized with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Chonnam medical journal·2026
Same author

ADAMTS4 elicits myeloid-derived immune cell recruitment and liver fibrogenesis in metabolic dysfunction-associated steatotic liver disease.

Signal transduction and targeted therapy·2026
Same author

Impact of vitamin D deficiency on 6-month culture conversion in nontuberculous mycobacterial pulmonary disease.

Scientific reports·2026
Same author

Factors associated with extended treatment duration in patients with drug-susceptible pulmonary tuberculosis: a prospective multicentre cohort study in South Korea.

BMC infectious diseases·2026

相关实验视频

Updated: Jun 11, 2025

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD &#8212; A Safe, Cost-Effective Approach
04:53

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

709

皮质类固醇治疗持续时间和剂量根据COVID-19后组织性肺炎的治疗开始时间.

Chang-Seok Yoon1, Hwa-Kyung Park1, Jae-Kyeong Lee1

  • 1Division of Pulmonology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea.

Chonnam medical journal
|October 9, 2024
PubMed
概括
此摘要是机器生成的。

在COVID-19后组织肺炎的早期类固醇治疗可能会减少治疗时间和剂量. 这项研究分析了91名患者,发现早期干预与COVID-19后肺部并发症的更好结果有关.

关键词:
皮质类固醇治疗 皮质类固醇治疗早期治疗启动早期治疗启动在COVID-19后组织肺炎

更多相关视频

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
13:27

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Published on: May 6, 2014

48.0K
Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

605

相关实验视频

Last Updated: Jun 11, 2025

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD &#8212; A Safe, Cost-Effective Approach
04:53

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

709
Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
13:27

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Published on: May 6, 2014

48.0K
Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

605

科学领域:

  • 肺部病理学 肺部病理学
  • 传染性疾病 传染性疾病
  • 药理学 药理学是指药理学的学科.

背景情况:

  • COVID-19经常导致肺部并发症,包括组织性肺炎.
  • 类固醇对于治疗COVID-19后组织性肺炎至关重要.
  • 有限的研究存在于早期类固醇启动对这种情况的好处.

研究的目的:

  • 研究COVID-19后组织性肺炎患者的类固醇开始时间和治疗持续时间和剂量之间的关联.

主要方法:

  • 追溯分析91名被诊断患有COVID-19后组织性肺炎的患者.
  • 患者被分为早期 (COVID-19 后<18.4 天) 和晚期 (COVID-19 后≥18.4 天) 类固醇治疗组.
  • 两组之间类固醇治疗持续时间和剂量的比较.

主要成果:

  • 早期治疗组 (n=55) 的平均类固醇持续时间为43.1±18.3天,剂量为0.5±0.3mg/kg/天.
  • 晚期治疗组 (n=36) 的平均持续时间较长,为59.1±22.6天,剂量较高,为0.8±0.3毫克/公斤/天 (p<0.01).
  • 类固醇开始时间显著影响了治疗持续时间 (β=0.80,p<0.01) 和剂量 (β=0.03,p<0.01).

结论:

  • 对COVID-19后组织性肺炎的早期类固醇启动与更短的治疗持续时间有关.
  • 较早的治疗也与较低的皮质类固醇剂量要求相关.
  • 这些发现表明,及时使用类固醇疗法在管理COVID-19后肺部并发症方面具有潜在的临床益处.